[Metastatic Renal Cell Carcinoma: Therapeutic Concepts for Non-medicinal Treatment]

Overview

Journal Urologe A

Specialty Urology

Date 2011 Jun 17

PMID 21678107

Authors

C Wiesner

A Haferkamp

Affiliations

Soon will be listed here.

Abstract

Metastatic renal cell carcinoma has a poor prognosis with a median overall survival rate of approximately 2 years. The current standard medicinal therapy includes the use of tyrosine kinase inhibitors or antiangiogenic substances, such as VEGF receptor antagonists. Improvement in clinical response is to be expected when surgical tumor debulking by nephrectomy or metastasectomy is performed before medicinal therapy is started and should be considered especially in patients with a good performance status. Additionally, complete resection of solitary or at least a limited number of metastases can potentially be done with curative intent. Radiotherapy remains the standard procedure for palliative therapy of brain metastases to reduce clinical symptoms and to improve intracerebral tumor control.

References

Alves A, Adam R, Majno P, Delvart V, Azoulay D, Castaing D . Hepatic resection for metastatic renal tumors: is it worthwhile?. Ann Surg Oncol. 2003; 10(6):705-10. DOI: 10.1245/aso.2003.07.024. View

Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B . Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol. 1999; 163(1):343-7. View

Andrews D, Scott C, Sperduto P, Flanders A, Gaspar L, Schell M . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363(9422):1665-72. DOI: 10.1016/S0140-6736(04)16250-8. View

Rini B, Campbell S . The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol. 2007; 177(6):1978-84. DOI: 10.1016/j.juro.2007.01.136. View

Wiesner C, Jakse G, Rohde D . Therapy of local recurrence of renal cell carcinoma. Oncol Rep. 2001; 9(1):189-92. View

Kutikov A, Uzzo R, Caraway A, Reese C, Egleston B, Chen D . Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2009; 106(2):218-23. PMC: 2906619. DOI: 10.1111/j.1464-410X.2009.09079.x. View

Hutterer G, Patard J, Colombel M, Belldegrun A, Pfister C, Guille F . Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer. 2007; 110(11):2428-33. DOI: 10.1002/cncr.23054. View

Gatenby R, Gawlinski E, Tangen C, Flanigan R, Crawford E . The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 2002; 62(18):5218-22. View

Eggener S, Yossepowitch O, Pettus J, Snyder M, Motzer R, Russo P . Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006; 24(19):3101-6. DOI: 10.1200/JCO.2005.04.8280. View

10.

Barbastefano J, Garcia J, Elson P, Wood L, Lane B, Dreicer R . Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010; 106(9):1266-9. DOI: 10.1111/j.1464-410X.2010.09323.x. View

11.

Tatsumi T, Herrem C, Olson W, Finke J, Bukowski R, Kinch M . Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003; 63(15):4481-9. View

12.

Flanigan R, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford E . Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171(3):1071-6. DOI: 10.1097/01.ju.0000110610.61545.ae. View

13.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

14.

Pantuck A, Zisman A, Belldegrun A . Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol. 2001; 19(2):72-9. View

15.

Murthy S, Kim K, Rice T, Rajeswaran J, Bukowski R, DeCamp M . Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?. Ann Thorac Surg. 2005; 79(3):996-1003. DOI: 10.1016/j.athoracsur.2004.08.034. View

16.

Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R . Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol. 2010; 186(4):210-7. DOI: 10.1007/s00066-010-2055-z. View

17.

Alexander J, Kudoh S, Melsop K, Hamilton T, Edinger M, Tubbs R . T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993; 53(6):1380-7. View

18.

Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T . Clinical study of brain metastasis of renal cell carcinoma. Eur Urol. 1999; 36(3):230-5. DOI: 10.1159/000068003. View

19.

Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

20.

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View